Morgan Stanley 2013 R&D Seminar: Reigniting Pharma
Upcoming SlideShare
Loading in...5
×
 

Morgan Stanley 2013 R&D Seminar: Reigniting Pharma

on

  • 876 views

Mikael Dolsten, M.D., Ph.D.

Mikael Dolsten, M.D., Ph.D.
President, Worldwide R&D

Statistics

Views

Total Views
876
Views on SlideShare
875
Embed Views
1

Actions

Likes
0
Downloads
9
Comments
0

1 Embed 1

http://www.media-ocean.de 1

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Morgan Stanley 2013 R&D Seminar: Reigniting Pharma Morgan Stanley 2013 R&D Seminar: Reigniting Pharma Presentation Transcript

  • Pfizer R&D Overview Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D May 10, 2013
  • 2 Forward-Looking Statements and Non-GAAP Financial Information • Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2012 Annual Report on Form 10-K/A and in our reports on Form 10-Q and Form 8-K. • Also, the discussions during this meeting will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles. Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer’s Current Report on Form 8-K dated April 30, 2013. • These reports are available on our website at www.pfizer.com in the "Investors - SEC Filings" section.
  • Continue to Execute on a Multi-year R&D Turnaround 3 2010 Drive the Transformation Shift to more value on lower cost base • Execute on recent product launches • Embed Precision Medicine • Continue to lead in novel collaborations • Increase portfolio quality, value, IRR • Improve clinical trial quality & consistency • Focus on culture & talent Deliver a Sustainable Flow of Innovative Therapies R&D delivers clear ROI • Increased focus and rigor in the portfolio • Integrated science & business • Moved Research to bioinnovation hubs • Advanced next-generation drug design • Launched CTI • Reduced R&D costs Lay the Foundation Interrogate and change the Pfizer R&D model • Important new product launches every year • Strong productivity and return for patients and shareholders • Emerge as nodal player in the health ecosystem
  • Recent Approvals Strong Pipeline Momentum 4 Phase 2 Phase 3 In Reg. 25 25 18 6 Phase 1 Total 74 Discovery Projects Pipeline Snapshot as of May 9, 2013
  • Highlights from the Mid-to-Late Stage Portfolio 5 Key Next Wave Programs Xeljanz Crohn’s, Ankylosing Spondylitis IL6, Anti-MAdCAM, Oral P38 Chronic Inflammatory Diseases SMO, PI3K mTOR Solid Tumor and Blood Cancers (SMO) S. aureus and C. difficile Vaccines Prophylaxis of key Hospital-acquired Infections Anti-PCSK9, SGLT-2 Cardiovascular and Type 2 Diabetes PDE5 Inhibitor and CCR 2/5 Inhibitor Chronic Kidney Disease GMI-1070* Vaso-occlusive Crisis, Sickle Cell Disease Biosimilar trastuzumab & rituximab Key Late Stage Programs Xeljanz Phase 3 studies in Ulcerative Colitis & Psoriasis Eliquis VTE Treatment & Prevention Palbociclib Advanced ER+HER2- Breast Cancer Inotuzumab Ozogamicin Aggressive Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia Dacomitinib Non-Small Cell Lung Cancer Meningococcal B Adolescent Vaccine Prevention of Meningococcal Infection *Pfizer has exclusive license from GlycoMimetics
  • Q&A